198 related articles for article (PubMed ID: 9157971)
21. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells.
Martelli L; Di Mario F; Ragazzi E; Apostoli P; Leone R; Perego P; Fumagalli G
Biochem Pharmacol; 2006 Sep; 72(6):693-700. PubMed ID: 16844093
[TBL] [Abstract][Full Text] [Related]
22. Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo.
Welters MJ; Fichtinger-Schepman AM; Baan RA; Jacobs-Bergmans AJ; Kegel A; van der Vijgh WJ; Braakhuis BJ
Br J Cancer; 1999 Jan; 79(1):82-8. PubMed ID: 10408697
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
24. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms.
Marchini S; Damia G; Broggini M; Pennella G; Ripamonti M; Marsiglio A; Geroni C
Cancer Res; 2001 Mar; 61(5):1991-5. PubMed ID: 11280757
[TBL] [Abstract][Full Text] [Related]
25. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.
Caserini C; Pratesi G; Tortoreto M; Bedogné B; Carenini N; Supino R; Perego P; Righetti SC; Zunino F
Clin Cancer Res; 1997 Jun; 3(6):955-61. PubMed ID: 9815771
[TBL] [Abstract][Full Text] [Related]
26. Functional analysis of the gene expression profiles of colorectal cancer cell lines in relation to oxaliplatin and cisplatin cytotoxicity.
Meynard D; Le Morvan V; Bonnet J; Robert J
Oncol Rep; 2007 May; 17(5):1213-21. PubMed ID: 17390068
[TBL] [Abstract][Full Text] [Related]
27. Cisplatin and oxaliplatin cytotoxic effects in sensitive and cisplatin-resistant human cervical tumor cells: time and mode of application dependency.
Martelli L; Ragazzi E; Di Mario F; Basato M; Martelli M
Anticancer Res; 2009 Oct; 29(10):3931-7. PubMed ID: 19846931
[TBL] [Abstract][Full Text] [Related]
28. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
Rice JR; Gerberich JL; Nowotnik DP; Howell SB
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2248-54. PubMed ID: 16609041
[TBL] [Abstract][Full Text] [Related]
29. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
Kelland LR; Sharp SY; O'Neill CF; Raynaud FI; Beale PJ; Judson IR
J Inorg Biochem; 1999 Oct; 77(1-2):111-5. PubMed ID: 10626362
[TBL] [Abstract][Full Text] [Related]
30. Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair.
Kondo A; Safaei R; Mishima M; Niedner H; Lin X; Howell SB
Cancer Res; 2001 Oct; 61(20):7603-7. PubMed ID: 11606400
[TBL] [Abstract][Full Text] [Related]
31. Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin.
Fink D; Nebel S; Norris PS; Baergen RN; Wilczynski SP; Costa MJ; Haas M; Cannistra SA; Howell SB
Int J Cancer; 1998 Aug; 77(5):741-6. PubMed ID: 9688308
[TBL] [Abstract][Full Text] [Related]
32. Revisiting [PtCl₂(cis-1,4-DACH)]: an underestimated antitumor drug with potential application to the treatment of oxaliplatin-refractory colorectal cancer.
Margiotta N; Marzano C; Gandin V; Osella D; Ravera M; Gabano E; Platts JA; Petruzzella E; Hoeschele JD; Natile G
J Med Chem; 2012 Aug; 55(16):7182-92. PubMed ID: 22788918
[TBL] [Abstract][Full Text] [Related]
33. The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells.
Fink D; Nebel S; Norris PS; Aebi S; Kim HK; Haas M; Howell SB
Br J Cancer; 1998 Mar; 77(5):703-8. PubMed ID: 9514047
[TBL] [Abstract][Full Text] [Related]
34. Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP.
Rennicke A; Voigt W; Mueller T; Fruehauf A; Schmoll HJ; Beyer C; Dempke W
Anticancer Res; 2005; 25(2A):1147-55. PubMed ID: 15868958
[TBL] [Abstract][Full Text] [Related]
35. Sequential X-irradiation induced acquired resistance to oxaliplatin but increased sensitivity to cisplatin in two human teratoma cell lines in vitro.
Eisenmann S; Voigt W; Müller T; Dempke W
Anticancer Res; 2010 Nov; 30(11):4471-6. PubMed ID: 21115895
[TBL] [Abstract][Full Text] [Related]
36. Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents.
Francia G; Man S; Teicher B; Grasso L; Kerbel RS
Mol Cell Biol; 2004 Aug; 24(15):6837-49. PubMed ID: 15254249
[TBL] [Abstract][Full Text] [Related]
37. Potential of the Akt inhibitor LY294005 to antagonize the efficacy of Cisplatin against HCT116 tumor cells in a DNA mismatch repair-dependent manner.
Fedier A; Erdmann R; Boulikas T; Fink D
Int J Oncol; 2006 Nov; 29(5):1303-10. PubMed ID: 17016665
[TBL] [Abstract][Full Text] [Related]
38. Cytotoxicity of cisplatin and cisdiammine-1,1-cyclobutane dicarboxylate in MGH-U1 cells grown as monolayers, spheroids, and xenografts.
Erlichman C; Vidgen D; Wu A
J Natl Cancer Inst; 1985 Sep; 75(3):499-505. PubMed ID: 3897683
[TBL] [Abstract][Full Text] [Related]
39. Specificity of platinum-DNA adduct repair.
Chaney SG; Vaisman A
J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
[TBL] [Abstract][Full Text] [Related]
40. Assessment of cytotoxicity, apoptosis and DNA damages in Colo320 colorectal cancer cells selected for oxaliplatin resistance.
Virag P; Brie I; Fischer-Fodor E; Perde-Schrepler M; Tatomir C; Balacescu O; Irimie A; Postescu ID
Cell Biochem Funct; 2011 Jul; 29(5):351-5. PubMed ID: 21491469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
